Literature DB >> 24449213

Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.

Erica M Sparkenbaugh1, Pichika Chantrathammachart, Jacqueline Mickelson, Joanne van Ryn, Robert P Hebbel, Dougald M Monroe, Nigel Mackman, Nigel S Key, Rafal Pawlinski.   

Abstract

Activation of coagulation and vascular inflammation are prominent features of sickle cell disease (SCD). Previously, we have shown that inhibition of tissue factor (TF) attenuates activation of coagulation and vascular inflammation in mouse models of SCD. In this study, we examined the mechanism by which coagulation proteases enhance vascular inflammation in sickle BERK mice. To specifically investigate the contribution of FXa and thrombin, mice were fed chow containing either rivaroxaban or dabigatran, respectively. In addition, we used bone marrow transplantation to generate sickle mice deficient in either protease activated receptor-1 (PAR-1) or protease activated receptor-2 (PAR-2) on nonhematopoietic cells. FXa inhibition and PAR-2 deficiency in nonhematopoietic cells attenuated systemic inflammation, measured by plasma levels of interleukin-6 (IL-6). In contrast, neither thrombin inhibition nor PAR-1 deficiency in nonhematopoietic cells affected plasma levels of IL-6 in sickle mice. However, thrombin did contribute to neutrophil infiltration in the lung, independently of PAR-1 expressed by nonhematopoietic cells. Furthermore, the TF-dependent increase in plasma levels of soluble vascular cell adhesion molecule-1 in sickle mice was not mediated by FXa or thrombin. Our data indicate that TF, FXa, and thrombin differentially contribute to vascular inflammation in a mouse model of SCD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24449213      PMCID: PMC3954055          DOI: 10.1182/blood-2013-08-523936

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

Review 1.  Pulmonary hypertension and nitric oxide depletion in sickle cell disease.

Authors:  H Franklin Bunn; David G Nathan; George J Dover; Robert P Hebbel; Orah S Platt; Wendell F Rosse; Russell E Ware
Journal:  Blood       Date:  2010-04-15       Impact factor: 22.113

2.  Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment?

Authors:  H J Wolters; H ten Cate; L L Thomas; D P Brandjes; A van der Ende; Y van der Heiden; L W Statius van Eps
Journal:  Br J Haematol       Date:  1995-07       Impact factor: 6.998

3.  Tissue factor expression by endothelial cells in sickle cell anemia.

Authors:  A Solovey; L Gui; N S Key; R P Hebbel
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

4.  Mortality in adults with sickle cell disease and pulmonary hypertension.

Authors:  Alem Mehari; Mark T Gladwin; Xin Tian; Roberto F Machado; Gregory J Kato
Journal:  JAMA       Date:  2012-03-28       Impact factor: 56.272

5.  Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

Authors:  Dagmar Kubitza; Michael Becka; Barbara Voith; Michael Zuehlsdorf; Georg Wensing
Journal:  Clin Pharmacol Ther       Date:  2005-10       Impact factor: 6.875

Review 6.  Tissue factor-factor VIIa signaling.

Authors:  L Vijaya Mohan Rao; Usha R Pendurthi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-11-29       Impact factor: 8.311

7.  Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

Authors:  Kenneth I Ataga; Charity G Moore; Cheryl A Hillery; Susan Jones; Herbert C Whinna; Dell Strayhorn; Cathy Sohier; Alan Hinderliter; Leslie V Parise; Eugene P Orringer
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

8.  Mast cell activation contributes to sickle cell pathobiology and pain in mice.

Authors:  Lucile Vincent; Derek Vang; Julia Nguyen; Mihir Gupta; Kathryn Luk; Marna E Ericson; Donald A Simone; Kalpna Gupta
Journal:  Blood       Date:  2013-06-17       Impact factor: 22.113

9.  Large-vessel occlusion in sickle cell disease: pathogenesis, clinical consequences, and therapeutic implications.

Authors:  R B Francis
Journal:  Med Hypotheses       Date:  1991-06       Impact factor: 1.538

10.  Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises.

Authors:  H Chaplin; M C Monroe; A C Malecek; L K Morgan; J Michael; W A Murphy
Journal:  East Afr Med J       Date:  1989-09
View more
  38 in total

1.  Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease.

Authors:  Erica M Sparkenbaugh; Pichika Chantrathammachart; Kasemsiri Chandarajoti; Nigel Mackman; Nigel S Key; Rafal Pawlinski
Journal:  Blood       Date:  2016-01-27       Impact factor: 22.113

Review 2.  Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.

Authors:  Dachuan Zhang; Chunliang Xu; Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

3.  Direct factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2/NF-κB signaling pathway.

Authors:  Meng Shi; Linlin Wang; Jian Zhou; Shimeng Ji; Ningfang Wang; Lin Tong; Jing Bi; Yuanlin Song; Jie Hu; Xiaofeng Chen
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

4.  Regulation of tissue factor gene expression in monocytes and endothelial cells: Thromboxane A2 as a new player.

Authors:  Michael Bode; Nigel Mackman
Journal:  Vascul Pharmacol       Date:  2014-05-21       Impact factor: 5.773

Review 5.  Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.

Authors:  Jens J Posma; Steven P Grover; Yohei Hisada; A Phillip Owens; Silvio Antoniak; Henri M Spronk; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

6.  An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms.

Authors:  Annette von Drygalski; Vikas Bhat; Andrew J Gale; Patricia M Averell; Thomas J Cramer; Darlene J Elias; John H Griffin; Laurent O Mosnier
Journal:  Blood Adv       Date:  2020-08-11

7.  The Current State of HIV and Aging: Findings Presented at the 10th International Workshop on HIV and Aging.

Authors:  Stephanie Shiau; Alexis A Bender; Jane A O'Halloran; Erin Sundermann; Juhi Aggarwal; Keri N Althoff; Jason V Baker; Steven Deeks; Linda P Fried; Stephen Karpiak; Maile Y Karris; Thomas D Marcotte; Jean B Nachega; Joseph B Margolick; Kristine M Erlandson; David J Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2020-09-23       Impact factor: 2.205

8.  Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.

Authors:  Megan Z Roberts; G Eric Gaskill; Julie Kanter-Washko; T Rogers Kyle; Brittany C Jones; Nicole M Bohm
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

9.  Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.

Authors:  Paritha I Arumugam; Eric S Mullins; Shiva Kumar Shanmukhappa; Brett P Monia; Anastacia Loberg; Maureen A Shaw; Tilat Rizvi; Janaka Wansapura; Jay L Degen; Punam Malik
Journal:  Blood       Date:  2015-08-18       Impact factor: 22.113

Review 10.  The emerging role of coagulation proteases in kidney disease.

Authors:  Thati Madhusudhan; Bryce A Kerlin; Berend Isermann
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.